Organization & Developments: Alder

Parents

2012: Alder Biopharma Snags $38M To Charge Ahead With Antibody Drugs (2012)
Alder Biopharmaceuticals, Inc. aims to identify, develop, and manufacture antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas.
Alder out-licenses its technologies to Bristol-Myers Squibb, Schering-Plough, Seattle Genetics, and Genmab.
Alder’s biologic product for the treatment of rheumatoid arthritis is known as ALD518.
BMS's upfront plus some near-term milestones leaves Alder with enough cash to roll ahead well into 2014
More efficient IL-6 therapy works as hoped, it can beat out therapies already on the market
New production technologies for antibodies, one of the hottest technologies in the industry
Schering-Plough, GenMab and Seattle Genetics are all on board as collaborators
Yeast-based approach to manufacturing antibodies, which is far more efficient than the traditional use of mammalian cells.